Department of Physiology, Semmelweis University School of Medicine, Budapest, Hungary.
Center for Rheumatology, Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary.
Nat Rev Drug Discov. 2020 Apr;19(4):253-275. doi: 10.1038/s41573-019-0054-z. Epub 2020 Jan 22.
Neutrophils are the most abundant circulating leukocytes, being the first line of defence against bacterial and fungal infections. However, neutrophils also contribute to tissue damage during various autoimmune and inflammatory diseases, and play important roles in cancer progression. The intimate but complex involvement of neutrophils in various diseases makes them exciting targets for therapeutic intervention but also necessitates differentiation of beneficial responses from potentially detrimental side effects. A variety of approaches to therapeutically target neutrophils have emerged, including strategies to enhance, inhibit or restore neutrophil function, with several agents entering clinical trials. However, challenges and controversies in the field remain.
中性粒细胞是循环白细胞中最丰富的细胞,是抵抗细菌和真菌感染的第一道防线。然而,中性粒细胞也在各种自身免疫性和炎症性疾病中导致组织损伤,并在癌症进展中发挥重要作用。中性粒细胞在各种疾病中的密切但复杂的参与使它们成为治疗干预的令人兴奋的靶点,但也需要将有益反应与潜在的有害副作用区分开来。已经出现了多种靶向中性粒细胞的治疗方法,包括增强、抑制或恢复中性粒细胞功能的策略,几种药物已经进入临床试验。然而,该领域仍然存在挑战和争议。